aflibercept

S01LA05

Forms & Strengths

Intravitreal injection: 2 mg/0.05 mL (40 mg/mL) in a single-dose vial
Intravitreal injection: 2 mg/0.05 mL in a pre-filled syringe
Intravitreal injection (High Dose): 8 mg/0.070 mL (114.3 mg/mL) in a single-dose vial

Adult Dosing

Neovascular (wet) AMD (2 mg): 2 mg (0.05 mL) monthly for the first 3 months, then 2 mg every 2 months (8 weeks)
Neovascular (wet) AMD (8 mg): 8 mg (0.07 mL) every 4 weeks for the first 3 doses, then every 8 to 16 weeks
Macular Edema following RVO: 2 mg (0.05 mL) monthly
Diabetic Macular Edema (2 mg): 2 mg (0.05 mL) monthly for the first 5 months, then 2 mg every 2 months (8 weeks)
Diabetic Macular Edema (8 mg): 8 mg (0.07 mL) every 4 weeks for the first 5 doses, then every 8 to 16 weeks
Diabetic Retinopathy: 2 mg (0.05 mL) monthly for the first 5 months, then 2 mg every 2 months (8 weeks)

Pediatric Dosing

Indications

Mechanism of Action

Recombinant fusion protein consisting of portions of human VEGF receptors 1 and 2 extracellular domains fused to the Fc portion of human IgG1
Acts as a soluble decoy receptor that binds VEGF-A, VEGF-B, and placental growth factor (PlGF)
Inhibits the binding and activation of cognate VEGF receptors, thereby suppressing endothelial cell proliferation, vascular permeability, and neovascularization

Contraindications

Adverse Reactions

Drug Interactions

Formal clinical drug interaction studies have not been performed with intravitreal administration
Potential additive systemic effects when combined with other inhibitors of VEGF

Curated Content: Needs Vetting Before Put to Clinical Use